Company: DMAAR
Filing Date: 2025-11-18
Form Type: 10-Q
Source: 0001213900-25-112096
Chunk: 9

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-11-18
Form: 10-Q
Item: Part I, Item 1
Chunk 9
---
 Business Combinations with one or more operating businesses or assets with a fair market value equal
to at least 80% of the net assets held in the Trust Account (as defined below) (excluding any deferred underwriting fees and taxes payable
on the interest earned on the Trust Account) at the time of the agreement to enter into the initial business combination. The Company
will only complete a Business Combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities
of the target or otherwise acquires a controlling interest in the target business sufficient for it not to be required to register as
an investment company under the Investment Company Act of 1940, as amended (the “Investment Company Act”).

5

DRUGS
MADE IN AMERICA ACQUISITION CORP.

NOTES
TO FINANCIAL STATEMENTS

SEPTEMBER
30, 2025

(Unaudited)

Following
the closing of the Initial Public Offering on January 29, 2025 and the over-allotment option closing on February 18, 2025 an amount of
$231,150,000 ($10.05 per Unit) from the net proceeds of the sale of the Units in the Initial Public Offering and the sale of the Private
Placement Units was placed in a trust account (“Trust Account”), located in the United States and invested only in U.S. government
treasury obligations with a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7
under the Investment Company Act which invest only in direct U.S. government treasury obligations and/or held as cash or cash items
(including in demand deposit accounts), as determined by the Company, until the earlier of: (i) the completion of a Business Combination;
(ii) the redemption of any Public Shares properly submitted in connection with a shareholder vote to amend the Company’s amended
and restated memorandum and articles of association (A) to modify the substance or timing of the Company’s obligation to allow
redemption in connection with its initial business combination or to redeem 100% of the Public Shares if the Company does not complete
its initial business combination within the Combination Period (as defined below) or (B) with respect to any other material provisions
relating to shareholders’ rights or pre-initial business combination activity; and (iii) the redemption of the Public Shares
if the Company has not completed an initial business combination